Ellen M. Dobrusin

1.9k total citations
24 papers, 1.5k citations indexed

About

Ellen M. Dobrusin is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Ellen M. Dobrusin has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Ellen M. Dobrusin's work include Cancer-related Molecular Pathways (7 papers), Quinazolinone synthesis and applications (5 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Ellen M. Dobrusin is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), Quinazolinone synthesis and applications (5 papers) and Protein Kinase Regulation and GTPase Signaling (5 papers). Ellen M. Dobrusin collaborates with scholars based in United States, New Zealand and United Kingdom. Ellen M. Dobrusin's co-authors include Dennis J. McNamara, David W. Fry, William A. Denny, Paul R. Keller, Wilbur R. Leopold, Jeff B. Smaill, Z.Y. Zhang, Derek Maclean, Tomi K. Sawyer and Alexander J. Bridges and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemistry.

In The Last Decade

Ellen M. Dobrusin

24 papers receiving 1.5k citations

Peers

Countries citing papers authored by Ellen M. Dobrusin

Since Specialization

Citations

This map shows the geographic impact of Ellen M. Dobrusin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen M. Dobrusin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen M. Dobrusin more than expected).

Fields of papers citing papers by Ellen M. Dobrusin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen M. Dobrusin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen M. Dobrusin. The network helps show where Ellen M. Dobrusin may publish in the future.

Co-authorship network of co-authors of Ellen M. Dobrusin

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen M. Dobrusin. A scholar is included among the top collaborators of Ellen M. Dobrusin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen M. Dobrusin. Ellen M. Dobrusin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of binding of phospholipase Cγ1 SH2 domains to phosphorylated epidermal growth factor receptor by phosphorylated peptides 2009 ·International journal of peptide & protein research ·Dennis J. McNamara, Ellen M. Dobrusin, (unknown), Stuart J. Decker, Alan R. Saltiel	1
2	Synthesis and structure–activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases 2007 ·European Journal of Medicinal Chemistry ·Jeff B. Smaill, Edward N. Baker, R J Booth, Alexander J. Bridges, James M. Dickson, Ellen M. Dobrusin, Ivan Ivanović, Alan J. Kraker, Ho H. Lee, Elizabeth A. Lunney, Daniel F. Ortwine, Brian D. Palmer, John Quin, C.J. Squire, Andrew M. Thompson, William A. Denny	28
3	Structure–activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1 2005 ·Bioorganic & Medicinal Chemistry Letters ·Brian D. Palmer, Jeff B. Smaill, Gordon W. Rewcastle, Ellen M. Dobrusin, Alan J. Kraker, Charles Watson Moore, Randall W. Steinkampf, William A. Denny	54
4	2-Aminoquinazoline inhibitors of cyclin-dependent kinases 2005 ·Bioorganic & Medicinal Chemistry Letters ·Yadagiri Bathini, Inderjit Singh, Patricia J. Harvey, Paul R. Keller, Rajeshwar Singh, Ronald G. Micetich, David W. Fry, Ellen M. Dobrusin, Peter L. Toogood	20
5	Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4 2005 ·Journal of Medicinal Chemistry ·(unknown), Patricia J. Harvey, Dennis J. McNamara, Joseph T. Repine, Paul R. Keller, John Quin, R J Booth, William L. Elliott, Ellen M. Dobrusin, David W. Fry, Peter L. Toogood	121
6	Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor. 2004 ·Cancer Research ·Michael D. Kaufman, Stephen D. Barrett, Cathlin Flamme, Joseph S. Warmus, (unknown), (unknown), (unknown), Haile Tecle, Judith S. Sebolt–Leopold, (unknown), Richard Gowan, Keri Van Becelaere, Ronald L. Merriman, Sally Przybranowski, Jeffrey F. Ohren, Christopher E. Whitehead, Wilbur R. Leopold, Ellen M. Dobrusin, Alexander J. Bridges	1
7	Cell Cycle and Biochemical Effects of PD 0183812 2001 ·Journal of Biological Chemistry ·David W. Fry, David C. Bedford, (unknown), (unknown), Paul R. Keller, Zhipei Wu, Ellen M. Dobrusin, Wilbur R. Leopold, Ali Fattaey, Michelle D. Garrett	90
8	Pyrido[2,3-d]pyrimidin-7-one Inhi-bitors of Cyclin-Dependent Kinases. 2001 ·Journal of Medicinal Chemistry ·Mark R. Barvian, Diane H. Boschelli, (unknown), Ellen M. Dobrusin, Ali Fattaey, (unknown), David W. Fry, Patricia J. Harvey, Paul R. Keller, Michelle D. Garrett, (unknown), Wilbur R. Leopold, Dennis J. McNamara, (unknown), Susanne Trumpp-Kallmeyer, Peter L. Toogood, (unknown), Erli Zhang	2
9	Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent Kinases 2000 ·Journal of Medicinal Chemistry ·Mark R. Barvian, Diane H. Boschelli, (unknown), Ellen M. Dobrusin, Ali Fattaey, (unknown), David W. Fry, Patricia J. Harvey, Paul R. Keller, Michelle D. Garrett, (unknown), Wilbur R. Leopold, Dennis J. McNamara, (unknown), Susanne Trumpp-Kallmeyer, Peter L. Toogood, Zhipei Wu, Erli Zhang	130
10	Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor 1998 ·Proceedings of the National Academy of Sciences ·David W. Fry, Alexander J. Bridges, William A. Denny, Annette M. Doherty, Kenneth D. Greis, James L. Hicks, Kenneth E. Hook, Paul R. Keller, Wilbur R. Leopold, Joseph A. Loo, Dennis J. McNamara, James M. Nelson, (unknown), Jeff B. Smaill, Susanne Trumpp-Kallmeyer, Ellen M. Dobrusin	344
11	Structure-Based Design of a Potent, Selective, and Irreversible Inhibitor of the Catalytic Domain of the erbB Receptor Subfamily of Protein Tyrosine Kinases 1997 ·Journal of Medicinal Chemistry ·Juswinder Singh, Ellen M. Dobrusin, David W. Fry, (unknown), Adrian Whitty, Dennis J. McNamara	89
12	C-Terminal Modifications of Histidyl-N-benzylglycinamides To Give Improved Inhibition of Ras Farnesyltransferase, Cellular Activity, and Anticancer Activity in Mice 1997 ·Journal of Medicinal Chemistry ·Dennis J. McNamara, Ellen M. Dobrusin, Daniele M. Leonard, (unknown), James S. Kaltenbronn, John Quin, Scott K. Bur, C. Thomas, Annette M. Doherty, Jeffrey D. Scholten, Karen K. Zimmerman, (unknown), Richard Gowan, (unknown), Wilbur R. Leopold, Sally Przybranowski, Judith S. Sebolt–Leopold	20
13	Determinants of Substrate Recognition in the Protein-tyrosine Phosphatase, PTP1 1996 ·Journal of Biological Chemistry ·(unknown), (unknown), Li Wu, Dennis J. McNamara, Ellen M. Dobrusin, W. Todd Miller	26
14	Differentiation of peptide molecular recognition by phospholipase Cγ‐1 Src homology‐2 domain and a mutant Tyr phosphatase PTP1b^C215S 1995 ·Protein Science ·Derek Maclean, Andrea M. Sefler, (unknown), Stuart J. Decker, Alan R. Saltiel, Juswinder Singh, Dennis J. McNamara, Ellen M. Dobrusin, Tomi K. Sawyer	2
15	Design of a potent peptide inhibitor of the epidermal growth factor receptor tyrosine kinase utilizing sequences based on the natural phosphorylation sites of phospholipase C-γ1 1994 ·Peptides ·David W. Fry, Amy McMichael, Juswinder Singh, Ellen M. Dobrusin, Dennis J. McNamara	14
16	Tyrosine Kinase Inhibitors. 3. Structure-Activity Relationships for Inhibition of Protein Tyrosine Kinases by Nuclear-Substituted Derivatives of 2,2'-Dithiobis(1-methyl-N-phenyl-1H-indole-3-carboxamide) 1994 ·Journal of Medicinal Chemistry ·Gordon W. Rewcastle, Brian D. Palmer, Ellen M. Dobrusin, David W. Fry, A J Kraker, William A. Denny	28
17	ChemInform Abstract: Tyrosine Kinase Inhibitors. Part 3. Structure‐Activity Relationships for Inhibition of Protein Tyrosine Kinases by Nuclear‐Substituted Derivatives of 2,2′‐Dithiobis(1‐methyl‐N‐phenyl‐1H‐indole‐3‐ carboxamide). 1994 ·ChemInform ·Gordon W. Rewcastle, Brian D. Palmer, Ellen M. Dobrusin, David W. Fry, (unknown), William A. Denny	3
18	Identification of Amino Acids in the N-Terminal SH2 Domain of Phospholipase C.gamma.1 Important in the Interaction with Epidermal Growth Factor Receptor 1994 ·Biochemistry ·(unknown), Dennis J. McNamara, Ellen M. Dobrusin, (unknown), Alan R. Saltiel, W. Todd Miller	15
19	Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3-dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2'-dithiobis(1H-indole-3-alkanoic acids) 1993 ·Journal of Medicinal Chemistry ·Andrew M. Thompson, Gordon W. Rewcastle, Moana Tercel, Ellen M. Dobrusin, David W. Fry, Alan J. Kraker, William A. Denny	30
20	Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B. 1993 ·Journal of Biological Chemistry ·Kim Milarski, (unknown), (unknown), Dennis J. McNamara, Ellen M. Dobrusin, Derek Maclean, (unknown), Z.Y. Zhang, Tomi K. Sawyer, Stuart J. Decker	89

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact